Veru announced that the FDA has declined to grant at this time the company’s request for Emergency Use Authorization, or EUA, for sabizabulin, Veru‘s novel microtubule disruptor, to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for Acute Respiratory Distress Syndrome. In communicating its decision, the FDA stated that despite the FDA declining to issue an EUA for sabizabulin at this time, the FDA remains committed to working with the Company for the development of sabizabulin.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VERU:
- Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
- Veru price target lowered to $14 from $20 at Oppenheimer
- Veru price target lowered to $14 from $18 at H.C. Wainwright
- Veru Inc Reported Earnings. Did it Beat Estimates?
- Veru Reports Fiscal 2023 First Quarter Financial Results
